Integra LifeSciences (NASDAQ:IART) Stock Crosses Above 200 Day Moving Average - Time to Sell?

Key Points

• Integra LifeSciences shares crossed above their 200-day moving average, trading at $16.12 versus the $14.94 average, with about 539,000 shares changing hands.
• Analyst sentiment remains cautious: the stock has an average rating of “Reduce” from MarketBeat, with five Holds, two Sells and one Buy, and an average price target of $18.86.
• The company exceeded quarterly expectations, reporting $0.56 in EPS versus a $0.48 estimate and $418.76 million in revenue; institutional investors own approximately 84.78% of the shares.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $14.94 and traded as high as $16.21. Integra LifeSciences shares last traded at $16.12, with a volume of 539,025 shares changing hands.

Analyst Ratings Changes

IART has been the subject of several research reports. Citigroup reaffirmed a "neutral" rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. BMO Capital Markets began coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They set a "market perform" rating and a $19.00 price objective on the stock. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating and set a $25.00 price objective for the company in a research note on Thursday, June 18th. Wells Fargo & Company upped their target price on Integra LifeSciences from $15.00 to $18.00 and gave the stock an "equal weight" rating in a report on Thursday, July 30th. Finally, Wall Street Zen cut Integra LifeSciences from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Reduce" and an average target price of $18.86.

Integra LifeSciences Price Performance

The firm has a market capitalization of $1.25 billion, a P/E ratio of -179.09, a P/E/G ratio of 0.82 and a beta of 1.21. The stock's fifty day simple moving average is $17.03 and its 200 day simple moving average is $14.94. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $418.76 million for the quarter, compared to analysts' expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Large investors have recently made changes to their positions in the business. Paradigm Capital Management Inc. NY purchased a new position in shares of Integra LifeSciences in the 2nd quarter valued at approximately $61,766,000. Wellington Management Group LLP grew its position in Integra LifeSciences by 12.4% during the 2nd quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company's stock worth $26,241,000 after purchasing an additional 160,814 shares during the last quarter. Bank of America Corp DE grew its position in Integra LifeSciences by 71.4% during the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company's stock worth $13,325,000 after purchasing an additional 589,408 shares during the last quarter. Invenomic Capital Management LP increased its stake in Integra LifeSciences by 78.3% during the 4th quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company's stock valued at $13,115,000 after purchasing an additional 463,729 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its stake in Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company's stock valued at $9,276,000 after purchasing an additional 211,774 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery and wound care. Its technologies are designed to help healthcare professionals treat complex conditions, repair damaged tissue and support surgical procedures.

The company's portfolio includes dural repair products and other neurosurgical implants, surgical instruments, regenerative tissue technologies, wound-care products and solutions for extremity reconstruction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.